I am surprised there hasn't been more talk about this med. One of the most talked about "downsides" I hear people talk about is the frustration with the plateaus
Weight loss plateau and amycretin
- Thread starter gpwdeux
- Start date
keangkong
GLP-1 Specialist
- Member Since
- Sep 2, 2024
- Posts
- 1,321
- Likes Received
- 3,549
Amycretin sounds extremely promising. By week 36, on average, people taking the injectable version has lost 24 percent of their bodyweight compared to 1 percent on placebo. My recollection is that on the highest dose of retatrutide, it took until week 48 to see similar results. Thus, based upon this early study, it looks like Amycretin may be superior in weight loss to Reta.
Malesu, Amycretin delivers unprecedented weight loss in early trial for obesity treatment
Here is the no paywall scholarly article: Dahl, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously - results from a phase 1b-2a randomised controlled study. Lancet (Published online 2025-06-21).
Here is the no paywall Wall Street Journal version: Chopping (Jun. 23, 2025).Novo Nordisk’s New Obesity Drug Beats Wegovy Weight Loss in Early Trial - The drugmaker is racing to develop the next generation of obesity medicines (Wall Street Journal).
Oddly, there was no much of a difference in weight loss between those who injected 20 mg per week and those who injected 60 mg per week.
Weight reduction was rapid, dose-dependent, and sustained. At their respective end-of-treatment timepoints, estimated mean percentage losses from baseline were:
Malesu, Amycretin delivers unprecedented weight loss in early trial for obesity treatment
Here is the no paywall scholarly article: Dahl, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously - results from a phase 1b-2a randomised controlled study. Lancet (Published online 2025-06-21).
Here is the no paywall Wall Street Journal version: Chopping (Jun. 23, 2025).Novo Nordisk’s New Obesity Drug Beats Wegovy Weight Loss in Early Trial - The drugmaker is racing to develop the next generation of obesity medicines (Wall Street Journal).
Oddly, there was no much of a difference in weight loss between those who injected 20 mg per week and those who injected 60 mg per week.
Weight reduction was rapid, dose-dependent, and sustained. At their respective end-of-treatment timepoints, estimated mean percentage losses from baseline were:
- 24.3% with 60 mg (week 36)
- 22.0% with 20 mg (week 36)
- 16.2% with 5 mg (week 28)
- 9.7% with 1.25 mg (week 20)
Last edited:
